Abstract
The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Current Diabetes Reviews
Title:Prediction and Diagnosis of Post Transplant Diabetes
Volume: 11 Issue: 3
Author(s): Christopher J. Yates and Solomon J. Cohney
Affiliation:
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Abstract: The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Export Options
About this article
Cite this article as:
Yates J. Christopher and Cohney J. Solomon, Prediction and Diagnosis of Post Transplant Diabetes, Current Diabetes Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573399811999150316105553
DOI https://dx.doi.org/10.2174/1573399811999150316105553 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on CRISPR-mediated Epigenome Editing: A Future Directive
for Therapeutic Management of Cancer
Current Drug Targets The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Gene Therapy for the Peripheral Nervous System: A Strategy to Repair the Injured Nerve?
Current Gene Therapy Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets General Aspects of Metal Toxicity
Current Medicinal Chemistry Raxofelast, (±)5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic Acid: A New Antioxidant to Modulate the Inflammatory Response During Ischemia-Reperfusion Injury and Impaired Wound Healing
Mini-Reviews in Medicinal Chemistry Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation
CNS & Neurological Disorders - Drug Targets Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Bone Disease in Diabetes
Current Diabetes Reviews Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Regulation of GABA Neurotransmission by Glutamic Acid Decarboxylase (GAD)
Current Pharmaceutical Design Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study
Current Topics in Medicinal Chemistry